[1] Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in
type 1 and type 2 diabetes.N Engl J Med 2017; 376: 1407–18.
[2] S.J. Haffner, H. Cassells, Hyperglycemia as a cardiovascular risk factor, Am. J. Me . 1013115 (Suppl. 8A) (2003) 6S–11S.
[3] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–57.
[4] Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228–39.
[5]. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine Rev 2012; 33:187–215.
[6] A.J. Motta, J. Koska, P. Reaven, R.Q. Migrino, Vascular protective effects of diabetes
medications that mimic or increase glucagon-like peptide-1 activity, Recent Pat. Cardiovasc. Drug Discov. 7 (2012) 2–9.
[7] M. Monami, I. Dicembrini, C. Nardini, I. Fiordelli, E. Mannucci, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials, Diabetes Obes. Metab. 16 (2014) 38–47.
[8] M. Monami, F. Cremasco, C. Lamanna, et al., Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials,Exp. Diabetes Res. 2011 (2011) 215764.
[9] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med. 6 (2009), e1000097.
[10]. Higgins, J. P. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).
[11]. Guyatt, G. H. et al. Incorporating considerations of resources use into grading recommendations. Bmj 336, 1170–1173, https://doi.org/10.1136/bmj.39504.506319.80 (2008).
[12] Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005;25(6):646–54.
[13] DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139–45.
[14] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60.
[15] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–34 [PubMed].
[16] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088–101 [PubMed].
[17] A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, D.M. Yellon, Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury, Diabetes 54 (2005) 146–151.
[18] T. Zhao, P. Parikh, S. Bhashyam, et al., Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts, J. Pharmacol. Exp. Ther. 317 (2006) 1106–1113.
[19] Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. 11 Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849–70.
[20] F. Sun, K. Yu, S. Wu, et al., Cardiovascular safety and glycemic control of glucagon- like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis, Diabetes Res. Clin. Pract. 98 (2012) 386–395.
[21] M. Monami, F. Cremasco, C. Lamanna, et al., Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials,Exp. Diabetes Res. 2011 (2011) 215764.
[22] R.Ratner,J.Han,D.Nicewarner,I.Yushmanova,B.J.Hoogwerf,L.Shen,Cardiovascu- lar safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes, Cardiovasc. Diabetol. 10 (2011) 22.
[23] S.P. Marso, J.B. Lindsey, J.M. Stolker, et al., Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical develop- ment studies, Diab. Vasc. Dis. Res. 8 (2011) 237–240.
[24] S.E. Inzucchi, D.K. McGuire, New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond, Circulation 117 (2008) 574–584.